A Combinatorial Strategy for Treating KRAS-mutant Lung Cancer

Overview

Journal Nature

Specialty Science

Date 2016 Jun 25

PMID 27338794

Citations 226

Authors

Eusebio Manchado

Susann Weissmueller

John P Morris 4th

Chi-Chao Chen

Ramona Wullenkord

Amaia Lujambio

Elisa de Stanchina

John T Poirier

Justin F Gainor

Ryan B Corcoran

Jeffrey A Engelman

Charles M Rudin

Neal Rosen

Scott W Lowe

Affiliations

Soon will be listed here.

Abstract

Therapeutic targeting of KRAS-mutant lung adenocarcinoma represents a major goal of clinical oncology. KRAS itself has proved difficult to inhibit, and the effectiveness of agents that target key KRAS effectors has been thwarted by activation of compensatory or parallel pathways that limit their efficacy as single agents. Here we take a systematic approach towards identifying combination targets for trametinib, a MEK inhibitor approved by the US Food and Drug Administration, which acts downstream of KRAS to suppress signalling through the mitogen-activated protein kinase (MAPK) cascade. Informed by a short-hairpin RNA screen, we show that trametinib provokes a compensatory response involving the fibroblast growth factor receptor 1 (FGFR1) that leads to signalling rebound and adaptive drug resistance. As a consequence, genetic or pharmacological inhibition of FGFR1 in combination with trametinib enhances tumour cell death in vitro and in vivo. This compensatory response shows distinct specificities: it is dominated by FGFR1 in KRAS-mutant lung and pancreatic cancer cells, but is not activated or involves other mechanisms in KRAS wild-type lung and KRAS-mutant colon cancer cells. Importantly, KRAS-mutant lung cancer cells and patients’ tumours treated with trametinib show an increase in FRS2 phosphorylation, a biomarker of FGFR activation; this increase is abolished by FGFR1 inhibition and correlates with sensitivity to trametinib and FGFR inhibitor combinations. These results demonstrate that FGFR1 can mediate adaptive resistance to trametinib and validate a combinatorial approach for treating KRAS-mutant lung cancer.

Citing Articles

Nanomedicine Innovations for Lung Cancer Diagnosis and Therapy.

Cardoso V, Bistaffa M, Sterman R, Lima L, Toldo G, Cancino-Bernardi J ACS Appl Mater Interfaces. 2025; 17(9):13197-13220.

PMID: 40045524 PMC: 11891907. DOI: 10.1021/acsami.4c16840.

Identifying traditional Chinese medicine combinations for breast cancer treatment based on transcriptional regulation and chemical structure.

Li S, Zhang L, Zhang W, Chen H, Hong M, Xia J Chin Med. 2025; 20(1):23.

PMID: 39953557 PMC: 11829537. DOI: 10.1186/s13020-025-01074-5.

Preclinical Models for Functional Precision Lung Cancer Research.

Yu J, Kiss Z, Ma W, Liang R, Li T Cancers (Basel). 2025; 17(1.

PMID: 39796653 PMC: 11718887. DOI: 10.3390/cancers17010022.

Targeting undruggable protein KRAS for cancer therapy: novel opportunities and challenges.

Yang X, Li X, Zhang Y, Zhang S, Zhang M, Sun C Future Med Chem. 2024; 17(2):143-147.

PMID: 39713985 PMC: 11749466. DOI: 10.1080/17568919.2024.2444865.

Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance.

Bortolot M, Torresan S, De Carlo E, Bertoli E, Stanzione B, Del Conte A Int J Mol Sci. 2024; 25(23).

PMID: 39684685 PMC: 11641714. DOI: 10.3390/ijms252312972.

References

Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S . Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell. 2014; 25(5):697-710. PMC: 4049532. DOI: 10.1016/j.ccr.2014.03.011. View

Samatar A, Poulikakos P . Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2014; 13(12):928-42. DOI: 10.1038/nrd4281. View

DuPage M, Dooley A, Jacks T . Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc. 2009; 4(7):1064-72. PMC: 2757265. DOI: 10.1038/nprot.2009.95. View

Traer E, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Martinez J . Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations. Blood. 2014; 123(10):1516-24. PMC: 3945862. DOI: 10.1182/blood-2013-07-518381. View

Sun C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F . Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep. 2014; 7(1):86-93. DOI: 10.1016/j.celrep.2014.02.045. View

Scholl C, Frohling S, Dunn I, Schinzel A, Barbie D, Kim S . Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 2009; 137(5):821-34. DOI: 10.1016/j.cell.2009.03.017. View

Luo J, Emanuele M, Li D, Creighton C, Schlabach M, Westbrook T . A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 2009; 137(5):835-48. PMC: 2768667. DOI: 10.1016/j.cell.2009.05.006. View

Chou T . Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70(2):440-6. DOI: 10.1158/0008-5472.CAN-09-1947. View

Corcoran R, Ebi H, Turke A, Coffee E, Nishino M, Cogdill A . EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012; 2(3):227-35. PMC: 3308191. DOI: 10.1158/2159-8290.CD-11-0341. View

10.

Villanueva J, Vultur A, Lee J, Somasundaram R, Fukunaga-Kalabis M, Cipolla A . Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010; 18(6):683-95. PMC: 3026446. DOI: 10.1016/j.ccr.2010.11.023. View

11.

Gozgit J, Wong M, Moran L, Wardwell S, Mohemmad Q, Narasimhan N . Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther. 2012; 11(3):690-9. DOI: 10.1158/1535-7163.MCT-11-0450. View

12.

Duncan J, Whittle M, Nakamura K, Abell A, Midland A, Zawistowski J . Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 2012; 149(2):307-21. PMC: 3328787. DOI: 10.1016/j.cell.2012.02.053. View

13.

Downward J . Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3(1):11-22. DOI: 10.1038/nrc969. View

14.

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

15.

Jackson E, Olive K, Tuveson D, Bronson R, Crowley D, Brown M . The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 2005; 65(22):10280-8. DOI: 10.1158/0008-5472.CAN-05-2193. View

16.

Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C . Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011; 54(20):7066-83. DOI: 10.1021/jm2006222. View

17.

Shimizu T, Tolcher A, Papadopoulos K, Beeram M, Rasco D, Smith L . The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res. 2012; 18(8):2316-25. DOI: 10.1158/1078-0432.CCR-11-2381. View

18.

Nazarian R, Shi H, Wang Q, Kong X, Koya R, Lee H . Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010; 468(7326):973-7. PMC: 3143360. DOI: 10.1038/nature09626. View

19.

Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D . Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012; 483(7387):100-3. DOI: 10.1038/nature10868. View

20.

Cox A, Fesik S, Kimmelman A, Luo J, Der C . Drugging the undruggable RAS: Mission possible?. Nat Rev Drug Discov. 2014; 13(11):828-51. PMC: 4355017. DOI: 10.1038/nrd4389. View